All manuscripts
Publications CAR T Cells TCR T Cells G-Rex®500M

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies

Published Journal International Reviews of Immunology

Share
17 pages Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies

Overview

This review presents three NIH case studies in which engineered T cell products were manufactured in culture bags, on an automated platform and in G-Rex® bioreactors. At the highest dose level, a 14-day rapid expansion in 5 L G-Rex® vessels yielded a median 123.3 × 10^9 cells, a 491-fold increase.

What this paper found

Three NIH case studies show that engineered T cell products can be manufactured in culture bags, on an automated platform or in G-Rex® bioreactors, with the choice guided by target dose, scalability and cost. CD30 CAR-T cells grown in culture bags reached a median of 2.2 × 10^9 cells at harvest on Day 7 across 25 products. CD19/CD22 bispecific CAR-T cells made on the CliniMACS Prodigy yielded a median of 1.883 × 10^9 cells, and all 24 products were successfully manufactured. E7 TCR T cells, whose target dose is orders of magnitude higher than for CAR-T cells, were expanded in G-Rex® bioreactors for a 14-day rapid expansion, giving a median of 123.3 × 10^9 cells and 491-fold expansion at the highest dose level.

Note: The case studies are single-institution experiences from early-phase trials; the authors note that more correlative studies are needed to learn which product features lead to the best patient response.

Special consideration is required for both scaling up and scaling out the process, with autologous therapies in particular requiring substantial scale-out capacity. — Hannah W. Song, Robert P. Somerville, David F. Stroncek, Steven L. Highfill, International Reviews of Immunology

Study details

Authors
Hannah W. Song, Robert P. Somerville, David F. Stroncek, Steven L. Highfill
Institution
Center for Cellular Engineering, Clinical Center, National Institutes of Health, Bethesda, USA
Journal
International Reviews of Immunology
Year
2022
PMID / PMC
PMID: 35486592 · PMC
G-Rex® model(s)
G-Rex®500M
Cell type(s)
CAR T Cells, TCR T Cells
Application area
Hematologic malignancy · Solid tumor

How G-Rex® was used

E7 TCR T cells from a 7 to 10-day culture with two retroviral transductions were seeded into g-Rex-500 bioreactors (5 L capacity): one vessel at the first two dose levels and 6–8 at dose level 3. The 14-day rapid expansion used irradiated PBMC feeders at 100:1, 30 μg/mL anti-CD3 and 3000 IU/mL IL-2, starting at 200 mL per vessel with media added on Days 4, 7 and 11 (800, 1200 and 1700 mL). Cultures were volume-reduced with the GatheRex, pooled and washed on a LOVO device. At the highest dose level the median harvest was 123.3 × 10^9 total T cells, a 491-fold expansion.

Ecosystem products: GatheRex

Explore related

Full citation

Song HW, Somerville RP, Stroncek DF, Highfill SL. Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapies. Int Rev Immunol. 2022;41(6):638-648.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →